Penny is responsible for all development activities for the company’s lead asset, ONL1204 Ophthalmic Solution. She brings over two decades of experience leading R&D organizations and portfolio clinical development strategies at major pharmaceutical companies and has a proven ability to advance assets through clinical development to regulatory approval and launch. As vice president and global head of specialty ophthalmology clinical development at Johnson & Johnson Innovative Medicine, she led the clinical development organization and was instrumental in building a portfolio of assets focused on both rare and common retinal conditions. Prior to joining Johnson & Johnson, Penny led the development and approval of multiple assets at Takeda Pharmaceutical across a number of disease areas including gastrointestinal, diabetes, and obesity. Penny holds a Bachelor of Science in medical technology from the University of Cincinnati and an MBA from Loyola University.